Background

This clinical trial focuses on patients with Malignant Peritoneal Mesothelioma (MPM). Currently, selecting the optimal treatment after surgery is challenging, necessitating a personalized approach. The research team aims to predict treatment efficacy using a patient-derived tumor cell cluster (PTC) model. This represents a differentiated strategy compared to conventional, uniform chemotherapy.

Study Design

Participants will be randomly assigned to either a standard treatment group or a personalized treatment group, each receiving six cycles of treatment. The standard group will receive Gemcitabine, Oxaliplatin, and Apatinib, with Sintilimab immunotherapy added for PD-L1-positive patients. The personalized treatment group will involve testing various chemotherapy, targeted therapy, and immunotherapy combinations in the PTC model to select the optimal drug. The primary endpoint is progression-free survival (PFS).

Expected Outcomes

If the PTC model accurately predicts actual patient treatment response, it could improve treatment success rates and minimize side effects. Successful implementation of the model could open the door to its application in other rare cancers, potentially expanding the market. However, there are risks, including the failure of the model to grow or discrepancies between in vitro and in vivo effects.

Industrial Significance

The study is funded by China's National Key R&D Program, demonstrating the government's commitment to innovative healthcare investments. Success could increase the value of companies developing personalized cancer treatment platforms, while companies focused on conventional chemotherapy may need to adjust their strategies. Failure could lead to concerns about recovering initial investments and maintaining technological credibility.